EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
|
EQS-News: BRAIN Biotech AG
/ Key word(s): Quarterly / Interim Statement/Study results
BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
ZWINGENBERG, Germany, February 25, 2026 – BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biosolutions for industry, has published its financial figures for the first three months of the fiscal year 2025/26. BRAIN Biotech Group generated Q1 revenue of € 11.9 million compared to € 13.1 million in the same period of the previous year, a decrease of 9.0 %. The group strongly improved the adjusted EBITDA to € 0.3 million from € -0.7 million in the same period last year, reflecting the strong performance of the BRAINBioIncubator segment. The BRAINBioIncubator segment benefitted from a milestone income of € 1.0 million from the deucrictibant program. The core segment BRAINBiocatalysts had the expected slow start to the year but is forecasted to show sequential growth over the next quarters. The company today announced very positive news on its BRAINBioIncubator participation SolasCure. SolasCure is an independent clinical development company in which BRAIN Biotech holds a 35 % stake and additional production rights to the active pharmaceutical ingredient (API) tarumase. SolasCure has now successfully completed an extension study of Phase 2a clinical development. The treatment of chronic wounds with Aurase® Wound Gel which combines a hydrogel with the enzymatic active ingredient tarumase shows both a 22 times more effective wound debridement and a 7 times accelerated healing compared to the current standard of care in the control group. SolasCure sees a total addressable market for the advanced treatment of chronic wounds of around US$ 4.3 billion in the US alone. With this positive clinical data, SolasCure is now seeking a larger financing round to secure funding for the next steps in clinical development. Adriaan Moelker, CEO BRAIN Biotech, comments: “I am really thrilled by the clinical data the SolasCure team has been able to demonstrate. There is a large global need for innovation in advanced wound care. Aurase Wound Gel has demonstrated to accelerate wound debridement and healing at the same time and has therefore the potential to become a best-in-class first line treatment for chronic wounds with a large addressable market. We at BRAIN Biotech are very proud to have invented this enzyme and to be an active partner in its commercialization.” Development of the segments Revenues in the core segment BRAINBiocatalysts (enzymes, microorganisms and ingredients) decreased by 16.3 % from € 11.9 million to € 10.0 million in the reporting period. This decrease is largely attributable to lower sales of baking enzymes and to the beverage industry. The company is currently commissioning a new state-of-the-art joint production site in the Netherlands. The move and combination of production sites to and within the Netherlands was one root cause of lower sales in the quarter next to lower general customer demand. BRAIN Biotech Group expects to finalize commissioning of the new plant during Q2 2025/26. Adjusted EBITDA in the BRAINBiocatalysts segment decreased from € 0.8 million to € 0.5 million, mainly due to lower revenues and negative product mix effects. The company is forecasting sequential revenue growth for the BRAINBiocatalysts segment over the next quarters after the soft start in Q1. Revenues within the BRAINBioIncubator segment (research-intensive R&D projects with industrial partners and own projects) rose strongly by € 0.7 million to € 1.9 million from € 1.2 million in the previous year. The company has been able to harvest a major milestone payment of € 1.0 million from the deucrictibant project for the treatment of hereditary angioedema. Milestone income in combination with lower personnel costs significantly improved adjusted EBITDA to € 0.7 million (€ - 0.7 million last year). The BRAIN Biotech Holding mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing costs, group financing and M&A activities. The adjusted EBITDA for the holding was slightly lower at € -0.9 million compared to the previous year and fully within the budget planning. Outlook For the financial year 2025/26, BRAIN Biotech AG maintains its outlook for the core segment BRAINBiocatalysts with expected sales around last year’s level and an associated adjusted EBITDA margin of around 10 %. The company upgrades its guidance for the segment BRAINBioIncubator to a positive adjusted EBITDA (previously around break-even). It maintains its view that revenues in this segment are expected to grow markedly, targeting around € 5 million in the financial year.
Key financial data for the first three months of the fiscal year 2025/26
1 Revenues + change in inventories + other income including R&D grants 2 The reconciliation from adjusted to unadjusted EBITDA can be found in the 3M report for the period ended December 31st, 2025
Further information BRAIN Biotech AG 3M Report 2025/26:
Financial Calendar: https://www.brain-biotech-group.com/en/investors/financial-publications-calendar/financial-calendar/ +++ Contact Media Dr. Stephanie Konle, PR & Corporate Communications Contact Investor Relations Martina Schuster, Investor Relations
BRAIN Biotech The BRAIN Biotech Group is a leader in researching, developing, and producing specialty enzymes, focusing on the food and life sciences industries. In addition, the group develops microbial production strains and scalable bioprocesses for the economic production of specialty enzymes and other proteins. BRAIN Biotech also offers customized biological solutions to the industry for more sustainable products and efficient processes. BRAIN Biotech AG is the parent company of the BRAIN Biotech Group. The company´s activities are divided into two business segments: BRAINBiocatalysts (development, production, and distribution of specialty enzymes, microorganisms, and ingredients) and BRAINBioIncubator (research-intensive development projects and pharmaceuticals). BRAIN Biotech operates its own fermentation facilities in the UK and has additional production sites in continental Europe and the US. BRAIN Biotech AG has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker symbol: BNN; ISIN: DE0005203947 / WKN: 520394). In the 2024/25 fiscal year, the group generated revenue of € 49.6 million with around 280 employees. For more information, visit: www.brain-biotech-group.com.
The BRAIN Biotech Group on social media and on the internet: BRAIN Biotech Gruppe Web: www.brain-biotech-group.com LinkedIn: https://www.linkedin.com/company/brainbiotech Threads: https://www.threads.net/@brainbiotechag Bluesky: https://bsky.app/profile/brain-biotech-group.com Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg
Biocatalysts Ltd (Production, Distribution) Website: https://www.biocatalysts.com/ LinkedIn: Biocatalysts Ltd on LinkedIn / BRAIN-Biocatalysts Life Science Solutions on LinkedIn
BRAIN Biotech Zwingenberg (Technologies & R&D Services) Website: www.brain-biotech.com LinkedIn: BRAIN Biotech Technologies & Services
AnalyticonDiscovery (R&D) Web: https://ac-discovery.com/ LinkedIn: https://www.linkedin.com/company/analyticon-discovery/
Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.
25.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | BRAIN Biotech AG |
| Darmstädter Straße 34-36 | |
| 64673 Zwingenberg | |
| Germany | |
| Phone: | +49 (0) 62 51 / 9331-0 |
| Fax: | +49 (0) 62 51 / 9331-11 |
| E-mail: | ir@brain-biotech.com |
| Internet: | www.brain-biotech.com |
| ISIN: | DE0005203947 |
| WKN: | 520394 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2280866 |
| End of News | EQS News Service |
|
|
2280866 25.02.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 38,23 | 38,39 | 45,51 | 55,34 | 54,63 | 49,62 | 52,70 | |
| EBITDA1,2 | -3,88 | -2,53 | -1,31 | -0,83 | -4,03 | -2,03 | -1,60 | |
| EBITDA-Margin3 | -10,15 | -6,59 | -2,88 | -1,50 | -7,38 | -4,09 | -3,04 | |
| EBIT1,4 | -8,23 | -6,55 | -5,65 | -5,48 | -8,85 | -7,15 | -6,40 | |
| EBIT-Margin5 | -21,53 | -17,06 | -12,42 | -9,90 | -16,20 | -14,41 | -12,14 | |
| Net Profit (Loss)1 | -9,02 | -4,68 | -6,34 | -8,11 | -11,10 | -11,83 | -9,75 | |
| Net-Margin6 | -23,59 | -12,19 | -13,93 | -14,66 | -20,32 | -23,84 | -18,50 | |
| Cashflow1,7 | -4,77 | -3,10 | -1,49 | -4,22 | -3,58 | -9,23 | -6,50 | |
| Earnings per share8 | -0,52 | -0,25 | -0,30 | -0,38 | -0,51 | -0,54 | -0,45 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| BRAIN Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 520394 | DE0005203947 | AG | 55,49 Mio € | 09.02.2016 | Halten | 8FXCPJH6+57 |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -9,77 | 0,00 | 0,00 | -5,53 | 30,14 | -6,01 | 1,12 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 11.03.2026 | 25.02.2026 | 28.05.2026 | 27.08.2026 | 14.01.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +0,16% | +10,48% | -3,17% | -6,51% | -72,89% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
